WO2004085474A3 - Method of producing an antibody to epidermal growth factor receptor - Google Patents

Method of producing an antibody to epidermal growth factor receptor Download PDF

Info

Publication number
WO2004085474A3
WO2004085474A3 PCT/US2004/008802 US2004008802W WO2004085474A3 WO 2004085474 A3 WO2004085474 A3 WO 2004085474A3 US 2004008802 W US2004008802 W US 2004008802W WO 2004085474 A3 WO2004085474 A3 WO 2004085474A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
antibody
growth factor
factor receptor
epidermal growth
Prior art date
Application number
PCT/US2004/008802
Other languages
French (fr)
Other versions
WO2004085474A2 (en
Inventor
Joseph Tarnowski
Daniel Velez
Joel Goldstein
Michael Barry
Diane Blumenthal
Girish Pendse
Original Assignee
Imclone Systems Inc
Joseph Tarnowski
Daniel Velez
Joel Goldstein
Michael Barry
Diane Blumenthal
Girish Pendse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Joseph Tarnowski, Daniel Velez, Joel Goldstein, Michael Barry, Diane Blumenthal, Girish Pendse filed Critical Imclone Systems Inc
Priority to EP04758046A priority Critical patent/EP1622941A2/en
Publication of WO2004085474A2 publication Critical patent/WO2004085474A2/en
Publication of WO2004085474A3 publication Critical patent/WO2004085474A3/en
Priority to US11/232,150 priority patent/US20060154334A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

The present invention is directed to a method of producing an antibody to Epidermal Growth Factor Receptor (EGFR). The method includes producing transformed cells that express EGFR antibodies, culturing the transformed cells, harvesting the transformed cells to collect the EGFR antibodies, and purifying the EGFR antibodies.
PCT/US2004/008802 2003-03-20 2004-03-22 Method of producing an antibody to epidermal growth factor receptor WO2004085474A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04758046A EP1622941A2 (en) 2003-03-20 2004-03-22 Method of producing an antibody to epidermal growth factor receptor
US11/232,150 US20060154334A1 (en) 2003-03-20 2005-09-20 Method of producing an antibody to epidermal growth factor receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45632403P 2003-03-20 2003-03-20
US60/456,324 2003-03-20
US52383603P 2003-11-19 2003-11-19
US60/523,836 2003-11-19
CA002450289A CA2450289A1 (en) 2003-03-20 2003-11-19 Method of producing an antibody to epidermal growth factor receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/232,150 Continuation-In-Part US20060154334A1 (en) 2003-03-20 2005-09-20 Method of producing an antibody to epidermal growth factor receptor

Publications (2)

Publication Number Publication Date
WO2004085474A2 WO2004085474A2 (en) 2004-10-07
WO2004085474A3 true WO2004085474A3 (en) 2004-12-23

Family

ID=34753238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/008802 WO2004085474A2 (en) 2003-03-20 2004-03-22 Method of producing an antibody to epidermal growth factor receptor

Country Status (2)

Country Link
CA (1) CA2450289A1 (en)
WO (1) WO2004085474A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT2163256E (en) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2007522157A (en) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Highly concentrated liquid formulation of anti-EGFR antibody
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
JP5276017B2 (en) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Use of anti-EGFR antibodies in the treatment of EGFR mutant mediated diseases
KR101805140B1 (en) 2007-03-01 2017-12-05 심포젠 에이/에스 Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
ES2609915T3 (en) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 addressed to the EGF receptor and derivatives and uses thereof
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014125382A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cetuximab with modified glycosylation and uses thereof
BR112015022971B1 (en) 2013-03-15 2022-05-17 Janssen Biologics B.V. Manufacturing methods to control the content of c-terminal lysine, galactose and sialic acid in recombinant proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3044236A2 (en) 2013-09-12 2016-07-20 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
CN105820248A (en) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 Method for preparing novel anti-EGFR monoclonal antibody and application thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATCC: "Hybri-Care Medium", INTERNET ARTICLE, 6 January 2003 (2003-01-06), XP002298392, Retrieved from the Internet <URL:atcc.org/SearchCatalogs/directdetail.cfm?collection=misc&atccnum=46-x> [retrieved on 20040928] *
CHANDLER L P ET AL: "A monoclonal antibody which inhibits epidermal growth factor binding has opposite effects on the biological action of epidermal growth factor in different cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 25 MAR 1985, vol. 260, no. 6, 25 March 1985 (1985-03-25), pages 3360 - 3367, XP002298388, ISSN: 0021-9258 *
DEZENGOTITA V M ET AL: "Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production.", BIOTECHNOLOGY AND BIOENGINEERING. 5 SEP 2000, vol. 69, no. 5, 5 September 2000 (2000-09-05), pages 566 - 576, XP002298391, ISSN: 0006-3592 *
HEIDEMANN-R ET AL.: "The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells", CYTOTECHNOLOGY, vol. 32, no. 2, February 2000 (2000-02-01), pages 157 - 167, XP002298390, ISSN: 0920-9069 *
MORRISON S L ET AL: "GENETICALLY ENGINEERED ANTIBODY MOLECULES AND THEIR APPLICATION", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 507, 1987, pages 187 - 198, XP009022405, ISSN: 0077-8923 *
ZHOU WEICHANG ET AL: "Fed-batch culture of recombinant NSO myeloma cells with high monoclonal antibody production", BIOTECHNOLOGY AND BIOENGINEERING, vol. 55, no. 5, 1997, pages 783 - 792, XP002298389, ISSN: 0006-3592 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8754062B2 (en) 2011-12-16 2014-06-17 Moderna Therapeutics, Inc. DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
CA2450289A1 (en) 2005-05-19
WO2004085474A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
WO2004085474A3 (en) Method of producing an antibody to epidermal growth factor receptor
HUP0600225A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DE60332596D1 (en) Diabody-type bispecific antibody
GB0312481D0 (en) Antibodies
WO2005075514A3 (en) Method for producing antibodies
WO2002085945A3 (en) Vhh single heavy chain antibody and a method for its preparation in a mammal
EP2298804A3 (en) Monoclonal antibody production by EBV transformation of B cells
WO2002043477A1 (en) Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
MXPA05009751A (en) Monoclonal antibody and hybridoma producing the same.
WO2005056606A3 (en) Optimized antibodies that target the epidermal growth factor receptor
WO2005073732A3 (en) Lc/ms method of analyzing high molecular weight proteins
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
PT1415158E (en) METHOD FOR SELECTING CELLS EXPRESSING ANTIBODIES
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2002085926A3 (en) Method for producing stable, regeneratable antibody arrays
EP1340981A3 (en) Antibodies for detecting amphetamine derivatives
WO2000056901A3 (en) Linear and circular expression elements
AU2001269445A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same
CA2473759A1 (en) Antibodies for detecting ecstasy-class analytes
CA2419698A1 (en) Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes
WO2005065015A3 (en) Neutralizing antibodies and methods of use thereof
DE60314132D1 (en) METHOD FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
WO2003055899A3 (en) Oxidized fungal antigens and methods of making and using thereof
EP1358318B8 (en) Hybridoma cell line g250 and its use for producing monoclonal antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11232150

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004758046

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004758046

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 11232150

Country of ref document: US